Melita Sun Jung serves as the Chief Business Officer at TERNS PHARMACEUTICALS INC, where she plays a pivotal role in steering the company's strategic business initiatives and fostering growth. With an extensive background in the biopharmaceutical industry, Melita has accumulated over two decades of experience in business development, corporate strategy, and alliance management. Prior to joining TERNS, she held significant positions at leading companies such as Gilead Sciences and Novartis, where she was instrumental in driving major collaborations and licensing deals that bolstered their portfolios. At Gilead Sciences, Melita was recognized for her leadership in negotiating and closing multi-billion-dollar partnerships that expanded the company's therapeutic reach. Her strategic foresight and negotiation skills were crucial in securing agreements that propelled Gilead's growth in critical areas such as oncology and virology. Before her tenure at Gilead, Melita worked at Novartis, where she managed key alliances and contributed to the development of innovative drug pipelines. Her expertise in navigating complex business landscapes and her ability to forge strong partnerships have been hallmarks of her career. In her current role at TERNS PHARMACEUTICALS INC, Melita is responsible for identifying and executing strategic opportunities that align with the company's mission to develop transformative treatments for serious diseases. Her leadership is vital in guiding TERNS through the competitive landscape of pharmaceutical development, ensuring that the company remains at the forefront of innovation. Melita's contributions are not only limited to business development but also extend to mentoring and developing her team, fostering a culture of excellence and collaboration within the organization.